<div id="readability-page-1"><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities researchers at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Bristol Myers Squibb in a research report issued on Tuesday, December 16th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $1.67 for the quarter, up from their prior forecast of $1.66. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb's FY2026 earnings at $6.02 EPS and Q1 2027 earnings at $1.36 EPS.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><p>Several other research analysts also recently commented on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, November 8th. Morgan Stanley  reaffirmed an &#34;underweight&#34; rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Weiss Ratings  reissued a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. The Goldman Sachs Group  reaffirmed a &#34;neutral&#34; rating and set a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, BMO Capital Markets  reaffirmed a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $54.62.</p><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p><b>Get Our Latest Stock Analysis on BMY</b></p><h2>Bristol Myers Squibb Trading Down 1.2%</h2><p>Bristol Myers Squibb stock opened at $53.56 on Thursday. The stock has a 50-day simple moving average of $47.35 and a 200 day simple moving average of $47.07. The stock has a market capitalization of $109.03 billion, a P/E ratio of 18.09, a PEG ratio of 8.30 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $63.33. </p><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. </p><h2>Institutional Investors Weigh In On Bristol Myers Squibb</h2><p>Large investors have recently bought and sold shares of the company. Norges Bank acquired a new position in  Bristol Myers Squibb during the second quarter valued at approximately $1,554,154,000.  Charles Schwab Investment Management Inc. increased its stake in shares of  Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company's stock valued at $3,277,456,000 after purchasing an additional 10,195,775 shares during the last quarter.  Arrowstreet Capital Limited Partnership raised its holdings in shares of  Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company's stock worth $523,599,000 after buying an additional 9,171,098 shares in the last quarter.  Man Group plc raised its stake in  Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter.  Finally, Franklin Resources Inc. lifted its holdings in shares of  Bristol Myers Squibb by 142.8% in the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company's stock worth $390,541,000 after acquiring an additional 4,961,869 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Bristol Myers Squibb Increases Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. Bristol Myers Squibb's dividend payout ratio  is currently 83.78%. </p><h2>About Bristol Myers Squibb</h2> (Get Free Report)<p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>What Are Treasury Bonds?</li><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li><li>There Are Different Types of Stock To Invest In</li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>Technology Stocks Explained: Here's What to Know About Tech</li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Zacks Research has increased its Q2 2026 EPS estimate for Bristol Myers Squibb to $1.67, up from $1.66. The consensus full-year earnings estimate is $6.74 per share. Several analysts have issued ratings, with a consensus rating of "Hold" and a target price of $54.62. Institutional investors have significantly increased their holdings in the company.</p>

Zacks Research Issues Positive Estimate for BMY Earnings